메뉴 건너뛰기




Volumn 14, Issue 3, 2015, Pages 154-161

A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer

Author keywords

Antiangiogenic therapy; Biomarkers; Combination Therapy; Panitumumab imaging; Pharmacodynamics

Indexed keywords

AFLIBERCEPT; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PLACENTAL GROWTH FACTOR; REGORAFENIB; SORAFENIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; NICOTINAMIDE; PROTEIN P21; VASCULOTROPIN A;

EID: 84938963326     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2015.02.007     Document Type: Article
Times cited : (25)

References (40)
  • 1
    • 84897078555 scopus 로고    scopus 로고
    • Accessed October 20, 2014
    • American Cancer Society. Cancer Facts and Figures 2014. Available at: http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/. Accessed October 20, 2014.
    • (2014) Cancer Facts and Figures
  • 2
    • 3242720345 scopus 로고    scopus 로고
    • Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
    • D. Cunningham, Y. Humblet, S. Siena, and et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337 345
    • (2004) N Engl J Med , vol.351 , pp. 337-345
    • Cunningham, D.1    Humblet, Y.2    Siena, S.3
  • 3
    • 0031800885 scopus 로고    scopus 로고
    • EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma
    • C. Messa, F. Russo, M.G. Caruso, and et al. EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma Acta Oncol 37 1998 285 289
    • (1998) Acta Oncol , vol.37 , pp. 285-289
    • Messa, C.1    Russo, F.2    Caruso, M.G.3
  • 4
    • 0027415146 scopus 로고
    • The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer
    • A. Mayer, M. Takimoto, E. Fritz, and et al. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer Cancer 71 1993 2454 2460
    • (1993) Cancer , vol.71 , pp. 2454-2460
    • Mayer, A.1    Takimoto, M.2    Fritz, E.3
  • 5
    • 70450195266 scopus 로고    scopus 로고
    • Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
    • N. Normanno, S. Tejpar, F. Morgillo, and et al. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC Nat Rev Clin Oncol 6 2009 519 527
    • (2009) Nat Rev Clin Oncol , vol.6 , pp. 519-527
    • Normanno, N.1    Tejpar, S.2    Morgillo, F.3
  • 6
    • 77949435827 scopus 로고    scopus 로고
    • Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer
    • A. Bardelli, and S. Siena Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer J Clin Oncol 28 2010 1254 1261
    • (2010) J Clin Oncol , vol.28 , pp. 1254-1261
    • Bardelli, A.1    Siena, S.2
  • 7
    • 59949091448 scopus 로고    scopus 로고
    • Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer
    • C. Bokemeyer, I. Bondarenko, A. Makhson, and et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 2009 663 671
    • (2009) J Clin Oncol , vol.27 , pp. 663-671
    • Bokemeyer, C.1    Bondarenko, I.2    Makhson, A.3
  • 8
    • 0036848820 scopus 로고    scopus 로고
    • Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice
    • D. Kedar, C.H. Baker, J.J. Killion, and et al. Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice Clin Cancer Res 8 2002 3592 3600
    • (2002) Clin Cancer Res , vol.8 , pp. 3592-3600
    • Kedar, D.1    Baker, C.H.2    Killion, J.J.3
  • 9
    • 0035394833 scopus 로고    scopus 로고
    • Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis
    • A. Viloria-Petit, T. Crombet, S. Jothy, and et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis Cancer Res 61 2001 5090 5101
    • (2001) Cancer Res , vol.61 , pp. 5090-5101
    • Viloria-Petit, A.1    Crombet, T.2    Jothy, S.3
  • 10
    • 55749088393 scopus 로고    scopus 로고
    • Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
    • S.M. Wilhelm, L. Adnane, P. Newell, and et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling Mol Cancer Ther 7 2008 3129 3140
    • (2008) Mol Cancer Ther , vol.7 , pp. 3129-3140
    • Wilhelm, S.M.1    Adnane, L.2    Newell, P.3
  • 11
    • 77958058348 scopus 로고    scopus 로고
    • Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells
    • E. Martinelli, T. Troiani, F. Morgillo, and et al. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells Clin Cancer Res 16 2010 4990 5001
    • (2010) Clin Cancer Res , vol.16 , pp. 4990-5001
    • Martinelli, E.1    Troiani, T.2    Morgillo, F.3
  • 12
    • 35648941728 scopus 로고    scopus 로고
    • Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study
    • L.B. Saltz, H.J. Lenz, H.L. Kindler, and et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study J Clin Oncol 25 2007 4557 4561
    • (2007) J Clin Oncol , vol.25 , pp. 4557-4561
    • Saltz, L.B.1    Lenz, H.J.2    Kindler, H.L.3
  • 13
    • 84860124769 scopus 로고    scopus 로고
    • Panitumumab: a summary of clinical development in colorectal cancer and future directions
    • G. Argiles, R. Dienstmann, E. Elez, and et al. Panitumumab: a summary of clinical development in colorectal cancer and future directions Future Oncol 8 2012 373 389
    • (2012) Future Oncol , vol.8 , pp. 373-389
    • Argiles, G.1    Dienstmann, R.2    Elez, E.3
  • 14
    • 84876734927 scopus 로고    scopus 로고
    • Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas
    • S. Bhattacharyya, K. Kurdziel, L. Wei, and et al. Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas Nucl Med Biol 40 2013 451 457
    • (2013) Nucl Med Biol , vol.40 , pp. 451-457
    • Bhattacharyya, S.1    Kurdziel, K.2    Wei, L.3
  • 15
    • 57849117384 scopus 로고    scopus 로고
    • New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
    • E.A. Eisenhauer, P. Therasse, J. Bogaerts, and et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
    • (2009) Eur J Cancer , vol.45 , pp. 228-247
    • Eisenhauer, E.A.1    Therasse, P.2    Bogaerts, J.3
  • 16
    • 77957966490 scopus 로고    scopus 로고
    • Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry
    • L. Li, M. Zhao, F. Navid, and et al. Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry J Chromatogr B Analyt Technol Biomed Life Sci 878 2010 3033 3038
    • (2010) J Chromatogr B Analyt Technol Biomed Life Sci , vol.878 , pp. 3033-3038
    • Li, L.1    Zhao, M.2    Navid, F.3
  • 17
    • 24644442153 scopus 로고    scopus 로고
    • A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma
    • C.H. Druzgal, Z. Chen, N.T. Yeh, and et al. A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma Head Neck 27 2005 771 784
    • (2005) Head Neck , vol.27 , pp. 771-784
    • Druzgal, C.H.1    Chen, Z.2    Yeh, N.T.3
  • 18
    • 0024536437 scopus 로고
    • Optimal two-stage designs for phase II clinical trials
    • R. Simon Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1989 1 10
    • (1989) Control Clin Trials , vol.10 , pp. 1-10
    • Simon, R.1
  • 19
    • 42649145667 scopus 로고    scopus 로고
    • Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    • R.G. Amado, M. Wolf, M. Peeters, and et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 2008 1626 1634
    • (2008) J Clin Oncol , vol.26 , pp. 1626-1634
    • Amado, R.G.1    Wolf, M.2    Peeters, M.3
  • 20
    • 44449142019 scopus 로고    scopus 로고
    • Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors
    • H. Minami, K. Kawada, H. Ebi, and et al. Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors Cancer Sci 99 2008 1492 1498
    • (2008) Cancer Sci , vol.99 , pp. 1492-1498
    • Minami, H.1    Kawada, K.2    Ebi, H.3
  • 21
    • 64649083367 scopus 로고    scopus 로고
    • Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301
    • A.A. Miller, D.J. Murry, K. Owzar, and et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301 J Clin Oncol 27 2009 1800 1805
    • (2009) J Clin Oncol , vol.27 , pp. 1800-1805
    • Miller, A.A.1    Murry, D.J.2    Owzar, K.3
  • 22
    • 84864361013 scopus 로고    scopus 로고
    • Sorafenib in advanced melanoma: a critical role for pharmacokinetics?
    • N. Pecuchet, C. Lebbe, O. Mir, and et al. Sorafenib in advanced melanoma: a critical role for pharmacokinetics? Br J Cancer 107 2012 455 461
    • (2012) Br J Cancer , vol.107 , pp. 455-461
    • Pecuchet, N.1    Lebbe, C.2    Mir, O.3
  • 23
    • 79960151990 scopus 로고    scopus 로고
    • Population pharmacokinetic analysis of sorafenib in patients with solid tumours
    • L. Jain, S. Woo, E.R. Gardner, and et al. Population pharmacokinetic analysis of sorafenib in patients with solid tumours Br J Clin Pharmacol 72 2011 294 305
    • (2011) Br J Clin Pharmacol , vol.72 , pp. 294-305
    • Jain, L.1    Woo, S.2    Gardner, E.R.3
  • 24
    • 20344362911 scopus 로고    scopus 로고
    • Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours
    • A. Awada, A. Hendlisz, T. Gil, and et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours Br J Cancer 92 2005 1855 1861
    • (2005) Br J Cancer , vol.92 , pp. 1855-1861
    • Awada, A.1    Hendlisz, A.2    Gil, T.3
  • 25
    • 59949102930 scopus 로고    scopus 로고
    • A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer
    • J.R. Hecht, E. Mitchell, T. Chidiac, and et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer J Clin Oncol 27 2009 672 680
    • (2009) J Clin Oncol , vol.27 , pp. 672-680
    • Hecht, J.R.1    Mitchell, E.2    Chidiac, T.3
  • 26
    • 59749091477 scopus 로고    scopus 로고
    • Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer
    • J. Tol, M. Koopman, A. Cats, and et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer N Engl J Med 360 2009 563 572
    • (2009) N Engl J Med , vol.360 , pp. 563-572
    • Tol, J.1    Koopman, M.2    Cats, A.3
  • 27
    • 77953641347 scopus 로고    scopus 로고
    • Phase II study of bevacizumab in combination with cetuximab plus irinotecan in irinotecan-refractory colorectal cancer (CRC) patients who have progressed on a bevacizumab-containing regimen (the BOND 2.5 study)
    • N.H. Segal, D. Reidy-Lagunes, M. Capanu, and et al. Phase II study of bevacizumab in combination with cetuximab plus irinotecan in irinotecan-refractory colorectal cancer (CRC) patients who have progressed on a bevacizumab-containing regimen (the BOND 2.5 study) J Clin Oncol 27 15 suppl 2009 abstract 4087
    • (2009) J Clin Oncol , vol.27 , Issue.15
    • Segal, N.H.1    Reidy-Lagunes, D.2    Capanu, M.3
  • 28
    • 84877755368 scopus 로고    scopus 로고
    • Mechanisms of resistance to anti-angiogenesis therapies
    • S. Giuliano, and G. Pages Mechanisms of resistance to anti-angiogenesis therapies Biochimie 95 2013 1110 1119
    • (2013) Biochimie , vol.95 , pp. 1110-1119
    • Giuliano, S.1    Pages, G.2
  • 29
    • 49849084552 scopus 로고    scopus 로고
    • Requirement of hypoxia-inducible factor-1alpha down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab
    • X. Li, Y. Lu, K. Liang, and et al. Requirement of hypoxia-inducible factor-1alpha down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab Mol Cancer Ther 7 2008 1207 1217
    • (2008) Mol Cancer Ther , vol.7 , pp. 1207-1217
    • Li, X.1    Lu, Y.2    Liang, K.3
  • 31
    • 75749096309 scopus 로고    scopus 로고
    • Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance
    • S. Kopetz, P.M. Hoff, J.S. Morris, and et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance J Clin Oncol 28 2010 453 459
    • (2010) J Clin Oncol , vol.28 , pp. 453-459
    • Kopetz, S.1    Hoff, P.M.2    Morris, J.S.3
  • 32
    • 63849088630 scopus 로고    scopus 로고
    • Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer
    • E. Van Cutsem, C.H. Kohne, E. Hitre, and et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 2009 1408 1417
    • (2009) N Engl J Med , vol.360 , pp. 1408-1417
    • Van Cutsem, E.1    Kohne, C.H.2    Hitre, E.3
  • 33
    • 33846148701 scopus 로고    scopus 로고
    • Sorafenib in advanced clear-cell renal-cell carcinoma
    • B. Escudier, T. Eisen, W.M. Stadler, and et al. Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
    • (2007) N Engl J Med , vol.356 , pp. 125-134
    • Escudier, B.1    Eisen, T.2    Stadler, W.M.3
  • 34
    • 79953301961 scopus 로고    scopus 로고
    • Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism
    • E. Bellini, A. Pia, M.P. Brizzi, and et al. Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism Ann Oncol 22 2011 988 990
    • (2011) Ann Oncol , vol.22 , pp. 988-990
    • Bellini, E.1    Pia, A.2    Brizzi, M.P.3
  • 35
    • 84855177596 scopus 로고    scopus 로고
    • Sorafenib-induced diarrhea and hypophosphatemia: mechanisms and therapeutic implications
    • O. Mir, R. Coriat, P. Boudou-Rouquette, and et al. Sorafenib-induced diarrhea and hypophosphatemia: mechanisms and therapeutic implications Ann Oncol 23 2012 280 281
    • (2012) Ann Oncol , vol.23 , pp. 280-281
    • Mir, O.1    Coriat, R.2    Boudou-Rouquette, P.3
  • 36
    • 80052458543 scopus 로고    scopus 로고
    • Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status
    • D.P. Modest, S. Stintzing, R.P. Laubender, and et al. Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status Anticancer Drugs 22 2011 913 918
    • (2011) Anticancer Drugs , vol.22 , pp. 913-918
    • Modest, D.P.1    Stintzing, S.2    Laubender, R.P.3
  • 37
    • 78049341541 scopus 로고    scopus 로고
    • Association of KRAS P.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
    • W. De Roock, D.J. Jonker, F. Di Nicolantonio, and et al. Association of KRAS P.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab JAMA 304 2010 1812 1820
    • (2010) JAMA , vol.304 , pp. 1812-1820
    • De Roock, W.1    Jonker, D.J.2    Di Nicolantonio, F.3
  • 38
    • 84867117207 scopus 로고    scopus 로고
    • Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab
    • S. Tejpar, I. Celik, M. Schlichting, and et al. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab J Clin Oncol 30 2012 3570 3577
    • (2012) J Clin Oncol , vol.30 , pp. 3570-3577
    • Tejpar, S.1    Celik, I.2    Schlichting, M.3
  • 39
    • 78049341541 scopus 로고    scopus 로고
    • Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
    • W. De Roock, D.J. Jonker, F. Di Nicolantonio, and et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab JAMA 304 2010 1812 1820
    • (2010) JAMA , vol.304 , pp. 1812-1820
    • De Roock, W.1    Jonker, D.J.2    Di Nicolantonio, F.3
  • 40
    • 84925300141 scopus 로고    scopus 로고
    • Phase II study of single agent cetuximab in KRAS G13D mutant metastatic colorectal cancer (MCRC)
    • M. Schirripa, S. Lonardi, C. Cremolini, and et al. Phase II study of single agent cetuximab in KRAS G13D mutant metastatic colorectal cancer (MCRC) Ann Oncol 25 suppl 2 2014 ii6 7
    • (2014) Ann Oncol , vol.25 , pp. ii6-ii7
    • Schirripa, M.1    Lonardi, S.2    Cremolini, C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.